34 completed, 4 unknown, 3 terminated, 2 active not recruiting. 13 Phase 2, 12 Phase 3, 8 Not applicable, 5 Phase 1, 5 Phase 4.
Follow linaclotide: new trials by email Literature Review of linaclotide trials Research Report on linaclotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Virtual Reality and Linaclotide for IBS-C Virtual Reality - Irritable Bowel Syndrome With Constipation | Not applicable | Recruiting | Mayo Clinic | 65 | 2024-05-31 | 2026-07-29 |
| Clinical Study of Bowel Preparation Before Colonoscopy OSS, OSS+Linzess, PEG-Interferon Alfa - Bowel Preparation | Not applicable | Completed | Jinling Hospital, China | 444 | 2023-08-01 | 2024-12-10 |
| A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide Linaclotide, Placebo - Functional Constipation | Phase 2 | Completed | AbbVie | 19 | 2023-04-27 | 2026-01-06 |
| A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation Placebo for Linaclotide, Linaclotide - Functional Constipation (FC), Chronic Idiopathic Constipation (CIC) | Phase 3 | Completed | AbbVie | 123 | 2022-12-29 | 2026-05-14 |
| GCC Agonist Signal in the Small Intestine Biopsy, Biospecimen Collection, Esophagogastroduodenoscopy - Barrett Esophagus, Gastroesophageal Reflux Disease | Phase 1 | Completed | University of Wisconsin, Madison | 43 | 2022-11-30 | 2026-04-07 |
| Application of Linaclotide Capsule in Bowel Preparation for Patients at High Risk of Inadequate Bowel Preparation 3 L PEG + linaclotide, 3 L PEG + placebo - Colonoscopy | Not applicable | Completed | Zhiguo Liu | 720 | 2022-08-01 | 2024-05-23 |
| Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy 3L PEG + Linaclotide, 3L PEG, 2L PEG + Linaclotide - Bowel Preparation for Colonoscopy | Not applicable | Completed | Changhai Hospital | 1607 | 2022-05-25 | 2024-06-20 |
| Effect and Safety of Polyethylene Glycol Combined With Linaclotide on Colon Cleansing for Patients With Chronic Constipation Linaclotide, Compound Polyethylene Glycol Electrolyte Powder - Bowel Preparation | Not applicable | Unknown | Second Affiliated Hospital of Xi'an Jiaotong University | 300 | 2021-09-01 | 2021-11-30 |
| Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation Linaclotide, LINZESS®, Placebo - Chronic Idiopathic Constipation | Phase 3 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 750 | 2021-03-05 | 2021-03-18 |
| Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders Linaclotide, Lactulose, Omeprazol - Functional Dyspepsia, Constipation-predominant Irritable Bowel Syndrome | Phase 4 | Unknown | RenJi Hospital | 78 | 2021-01-01 | 2021-12-13 |
| Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer Linaclotide, Placebo - Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8 | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 150 | 2019-10-30 | 2026-10-08 |
| Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation Linaclotide, Placebo - Functional Constipation | Phase 2 | Completed | Allergan | 35 | 2019-10-14 | 2022-04-26 |
| Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) Linaclotide, Placebo - Functional Constipation, Irritable Bowel Syndrome With Constipation | Phase 3 | Completed | AbbVie | 438 | 2019-10-01 | 2024-11-26 |
| A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Linaclotide, Placebo - Irritable Bowel Syndrome Characterized by Constipation | Phase 3 | Completed | Ironwood Pharmaceuticals, Inc. | 614 | 2018-06-20 | 2020-12-01 |
| Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases) linaclotide - Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases), Irritable Bowel Syndrome With Constipation (IBS-C) | Completed | Astellas Pharma Inc | 2475 | 2017-10-02 | 2024-10-18 | |
| A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C) Linaclotide, Placebo - Irritable Bowel Syndrome Characterized by Constipation | Phase 4 | Terminated | Ironwood Pharmaceuticals, Inc. | 20 | 2016-12-21 | 2021-12-06 |
| A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation linaclotide, Placebo - Chronic Constipation | Phase 3 | Completed | Astellas Pharma Inc | 186 | 2016-06-24 | 2024-10-18 |
| A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) Placebo, LIN Dose A, LIN Dose B - Functional Constipation in Children Ages 6-17 Years | Phase 2 | Completed | Forest Laboratories | 173 | 2015-11-03 | 2019-06-19 |
| An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Linaclotide - Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation | Phase 4 | Completed | Forest Laboratories | 828 | 2015-11-01 | 2019-08-22 |
| A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C - Irritable Bowel Syndrome With Constipation | Phase 2 | Terminated | Forest Laboratories | 101 | 2015-11-01 | 2020-12-28 |
Showing 20 of 44. Sign in to see all of them.
Constipation (8) · Irritable Bowel Syndrome (8) · Colorectal Neoplasms (2) · Barrett Esophagus (1) · Breast Feeding (1) · Colitis, Ulcerative (1) · Diabetes Mellitus (1) · Gastroesophageal Reflux (1) · Gastrointestinal Hemorrhage (1) · Gastrointestinal Neoplasms (1) · Opioid-Induced Constipation (1)
Ironwood Pharmaceuticals, Inc. (11) · Astellas Pharma Inc (7) · Forest Laboratories (6) · AbbVie (3) · Mayo Clinic (2) · Allergan (1) · AstraZeneca (1) · Augusta University (1) · Changhai Hospital (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Jinling Hospital, China (1) · RenJi Hospital (1) · Second Affiliated Hospital of Xi'an Jiaotong University (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Texas Tech University Health Sciences Center, El Paso (1)
United States (29) · China (7) · Japan (7) · Canada (6) · United Kingdom (5) · Bulgaria (3) · Germany (2) · Netherlands (2) · Australia (1) · Belgium (1) · Croatia (1) · Estonia (1) · Hungary (1) · Israel (1) · Italy (1)
Jeffrey M. Johnston, MD, FACP (4) · Anna Muslin (2) · Zhaoshen Li (2) · Adam D Farmer, PhD MRCP (1) · Bernard J Lavins, MD (1) · Brain Lacy, MD, PhD (1) · Chengwei Tang (1) · David S Weinberg (1) · Dongfeng Chen (1) · Dongmei Qian (1) · Huahong Wang (1) · Irene Sarosiek, MD (1)
PMID 20045700, PMID 20801122, PMID 21830967, PMID 23116208, PMID 24075889, PMID 25312449, PMID 30084233, PMID 30136447, PMID 30731474, PMID 32310620, PMID 32406112, PMID 33065589, PMID 34465695, PMID 35019221, PMID 36227782, PMID 36324245, PMID 38211604, PMID 38504394, PMID 38713137, PMID 38962910, PMID 40079184, PMID 40423516, PMID 41913506
2019 (2), N01CN00042 (1), P30CA014520 (1), UG1CA242635 (1)